FDA Inhaler Instructions Doubts Cause Delay in UT's PAH Drug

Shares of United Therapeutics Corp. fell 10 percent Monday after the Silver Spring, Md.-based firm said it expected a delay in the approval of Tyvaso (treprostinil), an inhaled version of the company's approved pulmonary arterial hypertension (PAH) drug Remodulin, an injectable drug. (BioWorld Today)